NCCN and Medlive Renew Collaboration to Enhance Cancer Care in China
United States-based National Comprehensive Cancer Network strengthens relationship with Chinese medical platform Medlive to broaden access to eminent oncology guidelines in China PLYMOUTH MEETING, Pa., July 30, 2024 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®), an alliance of leading cancer centers in the United States, is pleased to announce the renewal of...
NEURIM PHARMACEUTICALS RECEIVES POSITIVE CHMP OPINION ON SLENYTO® (PEDIATRIC PROLONGED-RELEASE MELATONIN) FOR THE TREATMENT OF INSOMNIA IN CHILDREN WITH NEUROGENETIC DISORDERS (NGDs)
TEL-AVIV, Israel, July 30, 2024 /PRNewswire/ -- Neurim Pharmaceuticals ("Neurim") announces that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending an extension to the existing indication to include the treatment of Insomnia in children with Neurogenetic disorders (NGDs). Slenyto® is a child appropriate prolonged release melatonin...
SK Telecom Expands ‘X Caliber’ Veterinary Diagnosis Assistant to Three Major Southeast Asian Markets
- SK Telecom signs agreements in Malaysia, Thailand and Vietnam to supply 'X Caliber', its AI-based veterinary diagnosis service, as demand for pet care grows SEOUL, South Korea, July 30, 2024 /PRNewswire/ -- SK Telecom (NYSE: SKM, "SKT") announced today that it has signed agreements to supply its artificial intelligence (AI)-based veterinary diagnosis assistant, 'X Caliber', to three major...
Bridge Biotherapeutics Announces Completion of Enrollment in the Phase 2a Clinical Study of BBT-877 for the Treatment of Idiopathic Pulmonary Fibrosis
SEONGNAM, South Korea, July 30, 2024 /PRNewswire/ -- Bridge Biotherapeutics (KQ288330), a clinical-stage biotech company based in South Korea developing novel drugs for fibrosis and cancer, today announced that patient participant enrollment has been completed in the Phase 2 clinical study of BBT-877, a novel autotoxin (ATX) inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF). The Phase...
CSafe launches reusable Silverpod pallet shipper to help pharma companies save on disposal costs and hit sustainability targets
New pallet improves cost and operational efficiency while reducing environmental impact; includes real-time visibility with cloud connectivity Key features include: Made of fully reusable components and recyclable PCM (phase change material) refrigerants New integrated real-time tracking device tracks GPS location, temperature, shock and tilt Rental model reduces disposal costs and inconvenience, supported by CSafe's recycle-reuse program Available to pharmaceutical businesses...
Menarini Announces Positive Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Efficacy, Safety and Tolerability of Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia
-- Achieved primary endpoint of LS mean reduction in LDL-C on top of maximally tolerated lipid modifying therapies at week 12 with statistically significant reduction (p<0.0001), which was sustained at week 52 (p<0.0001) -- -- Obicetrapib lowered LDL-C by 36.3% at week 12 and by 41.5% at week 52, compared to placebo --...
SOPHiA GENETICS Announces L’hôpital Universitaire Avicenne is Live on SOPHiA DDM™
The hospital will use the SOPHiA DDM™ Platform to enhance its testing and research of blood cancers BOSTON and ROLLE, Switzerland, July 29, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a leader in data-driven medicine, today announced that L'hôpital Universitaire Avicenne is implementing the SOPHiA DDM™ Platform....
Everise and Sanas Exclusively Partner to Transform Customer Experience With Real-Time AI Speech Understanding Technology
Partnership is exclusive within the healthcare BPO industry PLANTATION, Fla., July 29, 2024 /PRNewswire/ -- Everise, a leader in transforming customer service for global healthcare companies, today announced its exclusive partnership with Sanas, a global leader in real-time speech and accent conversion technology. The partnership provides Everise exclusive access to Sanas'...
Daewoong Pharmaceutical Receives Positive Recommendation from IDMC to Continue Developing its First-in-Class PRS Inhibitor, Bersiporocin
SEOUL, South Korea, July 29, 2024 /PRNewswire/ -- Daewoong Pharmaceutical (Co-CEOs Chang-Jae Lee and Seongsoo Park) announced a significant milestone in the development of 'Bersiporocin (DWN12088)', a first-in-class PRS inhibitor for idiopathic pulmonary fibrosis (IPF), has taken a significant step towards commercialization by demonstrating positive safety data from the Phase 2...
Despite External Challenges, WuXi AppTec Maintained Stable Operations in First Half of 2024; Revenue and Profit of the Second Quarter Both Steadily Improved QoQ as Expected, with Revenue Up...
Revenue Reached RMB9,259 Million in the Second Quarter, Excluding COVID-19 Commercial Projects, Up 0.3% Year-over-Year Revenue Reached RMB17,241 Million for the First Half, Excluding COVID-19 Commercial Projects, Down 0.7% Year-over-Year Net Profit Attributable to the Owners of the Company Reached RMB4,240 Million, and Diluted Earnings per Share (EPS) of RMB1.45 for the First Half Adjusted Non-IFRS Net Profit Attributable...
